Bausch Health Americas
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bausch Health Americas sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Bausch Health Americas: 168 sponsored US clinical trials, 6 recruiting.
Bausch Health Americas sponsors 168 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 144 completed. 86 of these trials are in Phase 3-4 (later-stage) and 68 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 6 trials.
Top-decile sponsor footprint
Bausch Health Americas ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
144 of 157 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 3 of 4
A Study of Acne Treatment in Children Ages 9 to 11
NCT00907335
Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
NCT00804141
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
NCT00801723
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
NCT00672139
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
NCT00724126
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
NCT00731679
(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
NCT00679432
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
NCT00672477
PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers
NCT00622375
Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.
NCT00714714
Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
NCT00640146
A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
NCT00528970
Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea
NCT00547898
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
NCT00612105
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
NCT00547586
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
NCT00529087
Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects
NCT00464802
Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
NCT00686920
Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance
NCT00447811
Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects
NCT00434395
Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects
NCT00444158
Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)
NCT00446134
Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX
NCT01366378
Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus
NCT00387309
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
NCT00401375
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
NCT00486031
Diarrhea Predominant Irritable Bowel Syndrome in Females
NCT00461526
Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide
NCT01366365
Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone
NCT00398502
A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence
NCT00605826
Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain
NCT00366431
Bioequivalence Study in Healthy Volunteers
NCT00387985
Dose Ranging Study in Healthy Methadone Maintenance Subjects
NCT00387491
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
NCT00408174
Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects
NCT00311350
Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan
NCT01367535
Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission
NCT00326209
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
NCT00269412
New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis
NCT00269438
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
NCT00328380
A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
NCT00269399
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
NCT00305383
Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)
NCT00360932
Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX
NCT01367483
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
NCT00101725
Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis
NCT00744016
Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis
NCT00767728
Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization
NCT01363323
DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up
NCT00444353
DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles
NCT00444210
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 37 |
| Phase 3 | 68 |
| Phase 4 | 18 |
What is open in the Bausch Health Americas pipeline
6 recruiting of 168 indexed (4% open); 144 completed (86%).
Phase mix: 86 late (III/IV) vs 68 early (I/II) (balanced across stages).
Top condition: Acne Vulgaris (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bausch Health Americas: open-pipeline peers nationwide
Peers matched on 168 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bausch Health Americas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- Sumitomo Pharma America · 168 trials · 4% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Bayer · 4% recruiting · 591 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
Related
What to do with this Bausch Health Americas page
168 registered trials is a research-attention snapshot, not an endorsement of Bausch Health Americas or any single study.
- 6 of Bausch Health Americas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Bausch Health Americas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bausch Health Americas pipeline card: 168 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.